Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Stock Short Interest Falls 39.5%

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the recipient of a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 7,784 shares, a decline of 39.5% from the September 30th total of 12,856 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average daily volume of 11,229 shares, the short-interest ratio is presently 0.7 days.

Hedge Funds Weigh In On Invesco Biotechnology & Genome ETF

A number of hedge funds have recently added to or reduced their stakes in the stock. Outlook Wealth Advisors LLC acquired a new position in Invesco Biotechnology & Genome ETF in the 3rd quarter valued at $1,468,000. Oakworth Capital Inc. bought a new stake in shares of Invesco Biotechnology & Genome ETF during the 3rd quarter valued at $59,000. Penobscot Investment Management Company Inc. acquired a new stake in shares of Invesco Biotechnology & Genome ETF during the 3rd quarter worth $1,892,000. Sowell Financial Services LLC acquired a new stake in shares of Invesco Biotechnology & Genome ETF during the 3rd quarter worth $298,000. Finally, Investment House LLC acquired a new stake in shares of Invesco Biotechnology & Genome ETF during the 3rd quarter worth $582,000.

Invesco Biotechnology & Genome ETF Trading Down 0.9%

NYSEARCA PBE opened at $102.50 on Friday. The company has a market cap of $445.88 million, a price-to-earnings ratio of 20.44 and a beta of 0.70. The company has a 50 day moving average of $96.99 and a 200-day moving average of $87.26. Invesco Biotechnology & Genome ETF has a 1-year low of $73.16 and a 1-year high of $104.24.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.